Table 1.
Summary of reasons for early termination of sc IFN β-1a treatment during the observational period, by subgroups.
| Reason for the early termination | Subgroup by sc IFN β-1a dosage |
Total | ||
|---|---|---|---|---|
| 22 µg thrice in week | 44 µg thrice in week | Dose escalation | ||
| Disease progression | 5 | 3 | 4 | 12 |
| Liver tests elevation | 2 | - | - | 2 |
| Pregnancy | 3 | - | - | 3 |
| Leukopenia | 1 | - | - | 1 |
| Tolerability issue: injection site reaction |
2 | 2 | 1 | 5 |
| Patient’s decision | 1 | 1 | - | 2 |
| Participation in a clinical trial | 1 | - | - | 1 |
| Change of location | 1 | - | - | 1 |
| Out of reimbursement criteria | 1 | - | - | 1 |
| Sum | 17 | 6 | 5 | 28 |